WO2008144556A1 - Methods of directly amplifying nucleic acids from crude samples - Google Patents

Methods of directly amplifying nucleic acids from crude samples Download PDF

Info

Publication number
WO2008144556A1
WO2008144556A1 PCT/US2008/063967 US2008063967W WO2008144556A1 WO 2008144556 A1 WO2008144556 A1 WO 2008144556A1 US 2008063967 W US2008063967 W US 2008063967W WO 2008144556 A1 WO2008144556 A1 WO 2008144556A1
Authority
WO
WIPO (PCT)
Prior art keywords
direct buffer
ssb
bsa
mgci2
kci
Prior art date
Application number
PCT/US2008/063967
Other languages
French (fr)
Inventor
Chien-Wei Chang
Dennis Y. Wang
Lori K. Hennessy
Original Assignee
Applera Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40027884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008144556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applera Corporation filed Critical Applera Corporation
Priority to CN200880016371A priority Critical patent/CN101796061A/en
Priority to CA2688571A priority patent/CA2688571A1/en
Priority to EP08755756A priority patent/EP2167524A4/en
Priority to JP2010508615A priority patent/JP2010527245A/en
Publication of WO2008144556A1 publication Critical patent/WO2008144556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • the present teachings generally relate to methods of directly amplifying nucleic acids from crude samples.
  • the present teachings provide a method of performing a polymerase chain reaction (PCR) comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer; removing the eluate from the incubated direct buffer wherein the eluate comprises the deoxyribonucleic acid from the crude sample; and performing a PCR on the deoxyribonucleic acid, 1 wherein the direct buffer comprises at least 5 PCR primer pairs, Tris-HCi at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/mi, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, and ssb (single-stranded binding protein) of at least 20ng/ul.
  • PCR polymerase chain reaction
  • the direct buffer comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, ssb at 60ng/ul.
  • the direct buffer further comprises Sodium Azide at .2 percent.
  • the ssb is T4 gene 32 protein from bacteriophage IA.
  • the present teachings provide a method of determining the identity of a human comprising; providing a crude sample comprising deoxyribonucleic acid from the human; incubating the crude sample with a direct buffer, wherein the direct buffer comprises a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acid from the crude sample; performing a PCR on the deoxyribonucleic acids from the crude sample to form a plurality of PCR amplicons, wherein each PCR amplicon has an ascertainable size; and, identifying the human by reference to size of the PCR amplicons, wherein the direct buffer further comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml
  • the present teachings provide a method of preparing nucleic acids for a downstream enzymatic manipulation comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer to form an eluate; removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acids from the crude sample; and performing a downstream enzymatic manipulation on the eluate, wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160- 960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
  • the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM
  • the downstream enzymatic manipulation is a PCR.
  • the present teachings provide a kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Tris- HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
  • the direct buffer comprises Tris- HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
  • the present teachings provide a reaction mixture comprising a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb at 20-60ng/ul.
  • the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb at 20-60ng/ul.
  • the term "crude sample” refers to a specimen of biological origin suspected of containing nucleic acids, which has not undergone substantial procedures for the isolation of those nucleic acids.
  • a sample of blood is a crude sample.
  • a sample of blood spotted on a paper, such as FTA paper commercially available from Whatman is a crude sample.
  • a buccal swab of cheek cells is another example of a crude sample.
  • Blood, blood on paper, and buccal swabs are illustrative crude samples.
  • One of skill in the art will recognize an enormous variety of other crude samples whose analysis would be facilitated by the present teachings.
  • the term "direct buffer” refers to a buffer into which a crude sample can be placed.
  • the direct buffer contains primers and enzyme for performing a downstream enzymatic manipulation, such as a polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the direct buffer allows for the liberation of the nucleic acids, and for their amplification from the eluate, without the need for any other purification. Illustrative cycling times and temperatures for PCR can be found in Sambrook et al., Molecular Cloning, 3 rd Edition.
  • the direct buffer of the present teachings focus on the use of the direct buffer for PCR, it will be appreciated that one of skill in the art can easily employ the direct buffer of the present teachings as a front-end procedure for other types of downstream enzymatic manipulations, for example reverse transcription using a reverse transcriptase, or an oligonucleotide ligation assay using a ligase.
  • the term "eluate" refers to the nucleic acid-containing solution which results from the incubation of the direct buffer with the crude sample.
  • the present teachings provide a direct buffer comprising Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, ssb at 20ng/ul or higher.
  • the direct buffer comprises Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
  • the direct buffer further comprises sodium azide, for example at .2 percent.
  • the ssb is the T4 gene 32 protein from bacteriophage T4, commercially available from, for example, Ambion, catalog #2424.
  • the desired concentration of ssb is 20-60 ng/ul. Higher concentrations are possible of course, but a ceiling appears at about 60ng/ul.
  • the ssb is present at 60ng/ul.
  • the reagents used in the direct buffer are readily available from commercial suppliers.
  • AmpliTaq Gold is commercially available for Applied Biosystems.
  • BSA is commercially available from a variety of sources, for example catalog number 10711454001 from Roche.
  • FTA paper is commercially available from Whatman.
  • the direct buffer comprises a plurality of PCR primer pairs.
  • the direct buffer comprises 5 primer pairs.
  • the direct buffer comprises 10 primer pairs.
  • the direct buffer comprises greater than 10 primer pairs.
  • the direct buffer does not comprise PCR primer pairs, but rather the PCR primer pairs are added to the eluate after the nucleic acids in the crude sample are liberated with the direct buffer. Examples
  • FTA paper Whatman
  • a 1.2mm disc punch of FTA paper was made and placed into the direct buffer containing PCR primers from the commercially available ldentifiler Human Identity Kit (Applied Biosystems). The disc punch was incubated in the direct buffer for the 10 minutes at room termperature with gentle vortex-mixing occasionally, and the eluate was then transferred into a fresh tube. (Additional dilution of eluate can be made with the PCR master mix if necessary.) PCR was then performed.
  • buccal swab samples were collected and placed in 50OuI TE buffer. The resulting suspension was heated at 97C for 5 minutes. 10 ul of the resulting suspension was used to set up a PCR in the direct buffer.
  • kits designed to expedite performing certain methods.
  • kits serve to expedite the performance of the methods of interest by assembling two or more components used in carrying out the methods.
  • kits may contain components in pre- measured unit amounts to minimize the need for measurements by end-users.
  • kits may include instructions for performing one or more methods of the present teachings.
  • the kit components are optimized to operate in conjunction with one another.
  • the present teachings provide a kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
  • the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
  • kits, and methods and reaction mixtures provided by the present teachings can be used with procedures for multiplexed PCR of degraded samples, as found for example in WO05054515 to Dimsoski and Woo.
  • the direct buffer in the kit comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
  • the direct buffer in the kit further comprises Sodium Azide at .2 percent.
  • the ssb in the kit is the T4 gene 32 protein from bacteriophage T4.

Abstract

The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification.

Description

METHODS OF DIRECTLY AMPLIFYING NUCLEIC ACIDS FROM CRUDE SAMPLES Field
[0001] The present teachings generally relate to methods of directly amplifying nucleic acids from crude samples. Introduction
[0002] Rapid and accurate detection of DNA profiles is a key aspect of forensic casework sample analysis. Crude samples such as blood and buccal swabs contain substances that can inhibit the activity of the polymerases used for PCR-based short tandem repeat (STR) typing. Historically, it has been necessary to remove inhibitors and purify DNA before performing downstream enzymatic manipulations such as PCR amplification. Many kinds of DNA isolation and purification methods and kits are commercially available. However, their use adds time and expense. Summary
[0003] The present teachings provide a method of performing a polymerase chain reaction (PCR) comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer; removing the eluate from the incubated direct buffer wherein the eluate comprises the deoxyribonucleic acid from the crude sample; and performing a PCR on the deoxyribonucleic acid, 1 wherein the direct buffer comprises at least 5 PCR primer pairs, Tris-HCi at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/mi, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, and ssb (single-stranded binding protein) of at least 20ng/ul. [0004] In some embodiments, the direct buffer comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, ssb at 60ng/ul.
[0005] In some embodiments, the direct buffer further comprises Sodium Azide at .2 percent.
[0006] In some embodiments, the ssb is T4 gene 32 protein from bacteriophage IA.
[0007] In some embodiments, the present teachings provide a method of determining the identity of a human comprising; providing a crude sample comprising deoxyribonucleic acid from the human; incubating the crude sample with a direct buffer, wherein the direct buffer comprises a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acid from the crude sample; performing a PCR on the deoxyribonucleic acids from the crude sample to form a plurality of PCR amplicons, wherein each PCR amplicon has an ascertainable size; and, identifying the human by reference to size of the PCR amplicons, wherein the direct buffer further comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, and ssb of at least 20ng/ul.
[0008] In some embodiments, the present teachings provide a method of preparing nucleic acids for a downstream enzymatic manipulation comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer to form an eluate; removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acids from the crude sample; and performing a downstream enzymatic manipulation on the eluate, wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160- 960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
[0009] In some embodiments, the downstream enzymatic manipulation is a PCR.
[0010] In some embodiments, the present teachings provide a kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Tris- HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
[0011] In some embodiments, the present teachings provide a reaction mixture comprising a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb at 20-60ng/ul. Description of Exemplary Embodiments
[0012] In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the word "a" or "an" means "at least one" unless specifically stated otherwise. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including," as well as other forms, such as "includes" and "included," is not limiting.
[0013] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Ail documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises are hereby expressly incorporated by reference in their entirety for any purpose. In the event that one or more of the incorporated documents defines a term that contradicts that term's definition in this application, this application controls. Some Definitions
[0014] As used herein, the term "crude sample" refers to a specimen of biological origin suspected of containing nucleic acids, which has not undergone substantial procedures for the isolation of those nucleic acids. For example, a sample of blood is a crude sample. Further, a sample of blood spotted on a paper, such as FTA paper commercially available from Whatman, is a crude sample. A buccal swab of cheek cells is another example of a crude sample. Blood, blood on paper, and buccal swabs are illustrative crude samples. One of skill in the art will recognize an enormous variety of other crude samples whose analysis would be facilitated by the present teachings.
[0015] As used herein, the term "direct buffer" refers to a buffer into which a crude sample can be placed. The direct buffer contains primers and enzyme for performing a downstream enzymatic manipulation, such as a polymerase chain reaction (PCR). The direct buffer allows for the liberation of the nucleic acids, and for their amplification from the eluate, without the need for any other purification. Illustrative cycling times and temperatures for PCR can be found in Sambrook et al., Molecular Cloning, 3rd Edition. While the present teachings focus on the use of the direct buffer for PCR, it will be appreciated that one of skill in the art can easily employ the direct buffer of the present teachings as a front-end procedure for other types of downstream enzymatic manipulations, for example reverse transcription using a reverse transcriptase, or an oligonucleotide ligation assay using a ligase.
[0016] As used herein, the term "eluate" refers to the nucleic acid-containing solution which results from the incubation of the direct buffer with the crude sample. Detailed Description
[0017] A large number of experiments were performed, varying the respective concentration of each of the ingredients of a desired direct buffer, including Tris-HCI, KCI, dNTPs, BSA, AmpliTaq Gold polymerase, MgCI2, and single stranded binding protein (SSB). These experiments used, for example, humic acid as a mimic for the inhibitors typically present in difficult to analyze samples of biological material, and hence served as an easy to produce proxy for crude samples. The results of these experiments yielded the following formulations.
[0018] In some embodiments, the present teachings provide a direct buffer comprising Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, ssb at 20ng/ul or higher.
[0019] In some embodiments, the direct buffer comprises Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul. [0020] In some embodiments, the direct buffer further comprises sodium azide, for example at .2 percent.
[0021] In some embodiments, the ssb is the T4 gene 32 protein from bacteriophage T4, commercially available from, for example, Ambion, catalog #2424. Generally, the desired concentration of ssb is 20-60 ng/ul. Higher concentrations are possible of course, but a ceiling appears at about 60ng/ul. In some embodiments, the ssb is present at 60ng/ul.
[0022] The reagents used in the direct buffer are readily available from commercial suppliers. For example, AmpliTaq Gold is commercially available for Applied Biosystems. BSA is commercially available from a variety of sources, for example catalog number 10711454001 from Roche. FTA paper is commercially available from Whatman.
[0023] In some embodiments, the direct buffer comprises a plurality of PCR primer pairs. For example, in some embodiments, the direct buffer comprises 5 primer pairs. In some embodiments, the direct buffer comprises 10 primer pairs. In some embodiments, the direct buffer comprises greater than 10 primer pairs. In some embodiments, the direct buffer does not comprise PCR primer pairs, but rather the PCR primer pairs are added to the eluate after the nucleic acids in the crude sample are liberated with the direct buffer. Examples
[0024] In a first example, blood was applied to FTA paper (Whatman) and air- dried. A 1.2mm disc punch of FTA paper was made and placed into the direct buffer containing PCR primers from the commercially available ldentifiler Human Identity Kit (Applied Biosystems). The disc punch was incubated in the direct buffer for the 10 minutes at room termperature with gentle vortex-mixing occasionally, and the eluate was then transferred into a fresh tube. (Additional dilution of eluate can be made with the PCR master mix if necessary.) PCR was then performed.
[0025] In a second example, 100-fold dilutions of blood were made with TE buffer (1OmM Tris-CI and .1mM EDTA at pH 8.0). 1 ul of diluted blood was used to set up a PCR in the direct buffer.
[0026] In a third example, buccal swab samples were collected and placed in 50OuI TE buffer. The resulting suspension was heated at 97C for 5 minutes. 10 ul of the resulting suspension was used to set up a PCR in the direct buffer. Exemplary Kits in Accordance with Some Embodiments of the Present Teachings
[0027] In some embodiments, the present teachings also provide kits designed to expedite performing certain methods. In some embodiments, kits serve to expedite the performance of the methods of interest by assembling two or more components used in carrying out the methods. In some embodiments, kits may contain components in pre- measured unit amounts to minimize the need for measurements by end-users. In some embodiments, kits may include instructions for performing one or more methods of the present teachings. In certain embodiments, the kit components are optimized to operate in conjunction with one another.
[0028] While the present teachings have been described in terms of these exemplary embodiments and experimental data, the skilled artisan will readily understand that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.
[0029] Thus, in some embodiments, the present teachings provide a kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul. Such a kit can be used, for example, in the identification of an organism such as a human by the collection of polymorphic microsatellites analyzed, using for example capillary electrophoresis, llustrative procedures for performing such human identification can be found for example in the Identifier HID kit, commercially available from Applied Biosystems, as well as U.S. Patents 6221598, 6479235, 5843660, and 7008771. In some embodiments, the kits, and methods and reaction mixtures provided by the present teachings can be used with procedures for multiplexed PCR of degraded samples, as found for example in WO05054515 to Dimsoski and Woo.
[0030] In some embodiments, the direct buffer in the kit comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
[0031] In some embodiments, the direct buffer in the kit further comprises Sodium Azide at .2 percent.
[0032] In some embodiments, the ssb in the kit is the T4 gene 32 protein from bacteriophage T4.

Claims

Claims
1. A method of performing a polymerase chain reaction (PCR) comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer; removing the eluate from the incubated direct buffer wherein the eluate comprises the deoxyribonucleic acid from the crude sample; and performing a PCR on the deoxyribonucleic acid, 1 wherein the direct buffer comprises at least 5 PCR primer pairs, Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, and ssb of at least 20ng/ul.
2. The method according to claim 1 wherein the direct buffer comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, ssb at 60ng/ul.
3. The method according to claim 2 wherein the direct buffer further comprises Sodium Azide at .2 percent.
4. The method according to claim 2 wherein the ssb is T4 gene 32 protein from bacteriophage T4.
5. A method of determining the identity of a human comprising; providing a crude sample comprising deoxyribonucleic acid from the human; incubating the crude sample with a direct buffer, wherein the direct buffer comprises a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat
(STR); removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acid from the crude sample; performing a PCR on the deoxyribonucleic acids from the crude sample to form a plurality of PCR amplicons, wherein each PCR amplicon has an ascertainable size; and, identifying the human by reference to size of the PCR amplicons, wherein the direct buffer further comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at1.25- 2.2 mM, and ssb of at least 20ng/ul.
6. The method according to claim 5 wherein the direct buffer comprises, Tris- HCI at 1 OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
7. The method according to claim 6 wherein the direct buffer further comprises Sodium Azide at .2 percent.
8. The method according to claim 6 wherein the ssb is T4 gene 32 protein from bacteriophage T4.
9. A method of preparing nucleic acids for a downstream enzymatic manipulation comprising; providing a crude sample comprising deoxyribonucleic acid; incubating the crude sample with a direct buffer to form an eluate; removing the eluate from the incubated direct buffer, wherein the eluate comprises the deoxyribonucleic acids from the crude sample; and performing a downstream enzymatic manipulation on the eluate, wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
10. The method according to claim 9 wherein the downstream enzymatic manipulation is a PCR.
11.The method according to claim 9 wherein the direct buffer comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul
12. The method according to claim 11 wherein the direct buffer further comprises Sodium Azide at .2 percent.
13. The method according to claim 11 wherein the ssb is T4 gene 32 protein from bacteriophage T4.
14. A kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Ths-HCI at 10-16 mM,
KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-
960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
15. The kit according to claim 14 wherein the direct buffer comprises, Tris-HCI at 1OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
16. The kit according to claim 15 wherein the direct buffer further comprises Sodium Azide at .2 percent.
17. The kit according to claim 15 wherein the ssb is T4 gene 32 protein from bacteriophage T4.
18. A reaction mixture comprising a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and wherein the direct buffer comprises Tris-HCI at 10-16 mM, KCI at 25-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 160-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCI2 at 1.25- 2.2 mM, and ssb of at least 20ng/ul.
19. The reaction mixture according to claim 18 wherein the direct buffer comprises, Tris- HCI at 1 OmM pH 8.3, KCI at 5OmM, dNTPs at 20OuM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at .16 units/ul, MgCI2 at 1.6mM, and ssb at 60ng/ul.
20. The reaction according to claim 19 wherein the direct buffer further comprises Sodium Azide at .2 percent.
21.The reaction mixture according to claimi 9 wherein the ssb is T4 gene 32 protein from bacteriophage T4.
PCT/US2008/063967 2007-05-17 2008-05-16 Methods of directly amplifying nucleic acids from crude samples WO2008144556A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN200880016371A CN101796061A (en) 2007-05-17 2008-05-16 Method from the direct amplification of nucleic acid of crude samples
CA2688571A CA2688571A1 (en) 2007-05-17 2008-05-16 Methods of directly amplifying nucleic acids from crude samples
EP08755756A EP2167524A4 (en) 2007-05-17 2008-05-16 Methods of directly amplifying nucleic acids from crude samples
JP2010508615A JP2010527245A (en) 2007-05-17 2008-05-16 Method for directly amplifying nucleic acid from a crude sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/750,316 US8153401B2 (en) 2007-05-17 2007-05-17 Method for direct amplification from crude nucleic acid samples
US11/750,316 2007-05-17

Publications (1)

Publication Number Publication Date
WO2008144556A1 true WO2008144556A1 (en) 2008-11-27

Family

ID=40027884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063967 WO2008144556A1 (en) 2007-05-17 2008-05-16 Methods of directly amplifying nucleic acids from crude samples

Country Status (6)

Country Link
US (1) US8153401B2 (en)
EP (1) EP2167524A4 (en)
JP (1) JP2010527245A (en)
CN (1) CN101796061A (en)
CA (1) CA2688571A1 (en)
WO (1) WO2008144556A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163120A1 (en) * 2010-06-21 2011-12-29 Life Technologies Corporation Compositions, methods and kits for nucleic acid synthesis and amplification
WO2012170907A3 (en) * 2011-06-08 2013-03-14 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US20170152546A1 (en) * 2012-10-24 2017-06-01 Ge Healthcare Uk Limited Direct Nucleic Acid Amplification Kit, Reagent and Method
EP3087205A4 (en) * 2013-12-25 2017-08-02 Coyote Bioscience Co., Ltd. Methods and systems for nucleic acid amplification
US9914964B2 (en) 2013-10-25 2018-03-13 Life Technologies Corporation Compounds for use in PCR systems and applications thereof
US10202639B2 (en) 2011-06-08 2019-02-12 Life Technologies Corporation Development of novel detergents for use in PCR systems
US11091801B2 (en) 2010-06-21 2021-08-17 Life Technologies Corporation Compositions, kits and methods for synthesis and/or detection of nucleic acids

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9563215B2 (en) 2012-07-14 2017-02-07 Causam Energy, Inc. Method and apparatus for actively managing electric power supply for an electric power grid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449603A (en) * 1989-10-24 1995-09-12 Stratagene Method for hybridizing nucleic acids using single-stranded nucleic acid binding protein
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US7008771B1 (en) * 1994-09-30 2006-03-07 Promega Corporation Multiplex amplification of short tandem repeat loci
US6413747B1 (en) 1994-10-03 2002-07-02 Shimadzu Corporation Enhancement of nucleic acid amplification by the addition of a polyamine
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
US6300069B1 (en) 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US20060286557A1 (en) * 2005-06-15 2006-12-21 Basehore Lee S Combined lysis and PCR buffer
US20080233587A1 (en) 2007-03-23 2008-09-25 Applera Corporation Method for direct amplification from crude nucleic acid samples

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"AmpFISTR. Identifier. PCR Amplification Kit User's Manual", APPLIED BIOSYSTEMS, 2006, pages 1-2, 4-3, 4-6, 4-34 - 2 *
ABU AL-SOUD ET AL.: "Effects of Amplification Facilitators on Diagnoastic PCR in the Presence of Blood Feces, and Meat", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 12, December 2000 (2000-12-01), pages 4463 - 4470, XP003016479 *
See also references of EP2167524A4 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163120A1 (en) * 2010-06-21 2011-12-29 Life Technologies Corporation Compositions, methods and kits for nucleic acid synthesis and amplification
US11091801B2 (en) 2010-06-21 2021-08-17 Life Technologies Corporation Compositions, kits and methods for synthesis and/or detection of nucleic acids
CN103038366A (en) * 2010-06-21 2013-04-10 生命技术公司 Compositions, methods and kits for nucleic acid synthesis and amplification
US9005895B2 (en) 2010-06-21 2015-04-14 Life Technologies Corporation Compositions, methods and kits for nucleic acid synthesis and amplification
EP3109326A1 (en) * 2010-06-21 2016-12-28 Life Technologies Corporation Compositions, methods and kits for nucleic acid synthesis and amplification using rt
US10676785B2 (en) 2011-06-08 2020-06-09 Life Technologies Corporation Development of novel detergents for use in PCR systems
WO2012170907A3 (en) * 2011-06-08 2013-03-14 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US11697841B2 (en) 2011-06-08 2023-07-11 Life Technologies Corporation Development of novel detergents for use in PCR systems
US20170114391A1 (en) * 2011-06-08 2017-04-27 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US10202639B2 (en) 2011-06-08 2019-02-12 Life Technologies Corporation Development of novel detergents for use in PCR systems
US10378050B2 (en) 2011-06-08 2019-08-13 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US11365443B2 (en) 2011-06-08 2022-06-21 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US9567628B2 (en) 2011-06-08 2017-02-14 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
US20170152546A1 (en) * 2012-10-24 2017-06-01 Ge Healthcare Uk Limited Direct Nucleic Acid Amplification Kit, Reagent and Method
US10907201B2 (en) * 2012-10-24 2021-02-02 Global Life Sciences Solutions Operations UK Ltd Direct nucleic acid amplification kit, reagent and method
US9914964B2 (en) 2013-10-25 2018-03-13 Life Technologies Corporation Compounds for use in PCR systems and applications thereof
US11479814B2 (en) 2013-10-25 2022-10-25 Life Technologies Corporation Compounds for use in PCR systems and applications thereof
US10683539B2 (en) 2013-10-25 2020-06-16 Life Technologies Corporation Compounds for use in PCR systems and applications thereof
AU2014372983B2 (en) * 2013-12-25 2019-01-24 Coyote Bioscience Co., Ltd. Methods and systems for nucleic acid amplification
US10465239B2 (en) 2013-12-25 2019-11-05 Coyote Bioscience Co., Ltd. Methods and systems for nucleic acid amplification
AU2014372983C1 (en) * 2013-12-25 2019-08-08 Coyote Bioscience Co., Ltd. Methods and systems for nucleic acid amplification
EP3087205A4 (en) * 2013-12-25 2017-08-02 Coyote Bioscience Co., Ltd. Methods and systems for nucleic acid amplification

Also Published As

Publication number Publication date
CA2688571A1 (en) 2008-11-27
EP2167524A4 (en) 2011-01-12
US8153401B2 (en) 2012-04-10
US20080286772A1 (en) 2008-11-20
CN101796061A (en) 2010-08-04
EP2167524A1 (en) 2010-03-31
JP2010527245A (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US9518302B2 (en) Method for direct amplification from crude nucleic acid samples
JP6966681B2 (en) Amplification with primers with limited nucleotide composition
US8153401B2 (en) Method for direct amplification from crude nucleic acid samples
EP3252174A1 (en) Compositions, methods, systems and kits for target nucleic acid enrichment
JP5367078B2 (en) Improved lysis and reverse transcription for mRNA quantification
US20080145898A1 (en) Sequencing methods
EP2722401B1 (en) Addition of an adaptor by invasive cleavage
US10858694B2 (en) Methods and reagents for reverse-transcription polymerase chain reaction
US20080233587A1 (en) Method for direct amplification from crude nucleic acid samples
US10822645B1 (en) Methods and reagents for reverse-transcription polymerase chain reaction
JP4186270B2 (en) Nucleic acid synthesis method
JP4186269B2 (en) Nucleic acid synthesis method
JP4187057B2 (en) Nucleic acid synthesis method

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880016371.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755756

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2688571

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010508615

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008755756

Country of ref document: EP